Results 201 to 210 of about 126,956 (339)

Gankyrin‐Protein Interactions in GI Cancers: A Novel Target of New Therapeutics

open access: yesChronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Gankyrin (PSMD10) is a 25 kDa oncogenic protein and regulatory subunit of the 26S proteasome, characterized by a sevenfold ankyrin repeat domain. Gankyrin is overexpressed in various malignancies, particularly gastrointestinal (GI) cancers. Gankyrin contributes to tumorigenesis by modulating key signaling pathways and engaging in oncogenic ...
Shuang Li   +4 more
wiley   +1 more source

Molecular Docking and Target‐Specific Binding Profiles of Benzosuberane‐Based Compounds

open access: yesChemMedChem, EarlyView.
Benzosuberane represents a promising scaffold in medicinal chemistry. Several benzosuberane‐based derivatives are described in this review as anticancer agents, including antivascular agents, DNA‐intercalators, receptor modulators and kinase inhibitors.
Michail A. Saragatsis   +3 more
wiley   +1 more source

Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing Signals

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Data science approaches have been increasingly implemented in healthcare big data to evaluate the safety and effectiveness of drugs. Association discovery is a data mining approach that finds potentially associated elements in high‐dimensional data. We present a novel implementation of the association discovery approach in longitudinal healthcare data ...
George S. Q. Tan   +6 more
wiley   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons   +17 more
wiley   +1 more source

Critical Evaluation of Methods for the Identification of Aneugens

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
ABSTRACT The genotoxic potential of chemicals must be evaluated in regulatory safety assessment settings, including but not limited to, the development of new pharmaceuticals, industrial chemicals, food and cosmetic ingredients, and agrochemicals. Initial assessment of the chromosome‐damaging potential of chemicals is often conducted in mammalian cells
Xiaowen Sun   +8 more
wiley   +1 more source

STIP1 drives Metabolic Reprogramming in Esophageal Squamous Cell Carcinoma via AHCY‐LDHA Axis

open access: yesExploration, EarlyView.
A schematic model illustrating that LCA can inhibit ESCC growth by inhibiting the STIP1/AHCY/LDHA axis. In brief. Jin et al. demonstrated that targeting STIP1 can significantly inhibit the progression of esophageal squamous cell carcinoma. The high expression of STIP1 increased the interaction between AHCY and LDHA and then AHCY recruits PRMT3 to ...
Guoguo Jin   +16 more
wiley   +1 more source

Natural Products Targeting the EGFR/HER2 Axis in Tumorigenesis: Interpretation of Molecular Mechanisms and Recent Insights Into Synergistic Strategies for Cancer Therapy

open access: yesFood Frontiers, EarlyView.
Schematic overview illustrating the anticancer mechanisms of selected natural products (resveratrol, quercetin, berberine) targeting EGFR and HER2 signaling pathways in tumor cells. These compounds inhibit receptor activation and downstream oncogenic cascades, including PI3K/Akt/mTOR, MAPK/ERK, and STAT3 pathways.
Iman Ramli   +8 more
wiley   +1 more source

Transplantation and other aspects of surgery of the liver [PDF]

open access: yes, 1984
Iwatsuki, S   +3 more
core  

Home - About - Disclaimer - Privacy